Potential New Treatment Options for Drug-Resistant Mantle Cell Lymphoma
the Cancer Therapy Advisor take:
Researchers conducted a genomic analyses of healthy tissues and tumors from patients with mantle cell lymphomas who did not respond to treatment with ibrutinib or initially responded but eventually experienced disease progression while receiving ibrutinib treatment.
According to a study recently published in Cancer Discovery, the journal of the American Associated for Cancer Research, the genomic analyses identified explanations for both forms of drug resistance and provided insight on how to effectively treat these patients in the clinic.
The percentage of patients with mantle cell lymphoma who do not respond to ibrutinib treatment is about 32%, otherwise the drug shows an “unprecedented clinical activity against mantle cell lymphoma,” said Selina Chen-Kiang, PhD, lead researcher. Dr. Chen-Kiang also noted that researchers are finding that patients whose lymphomas respond to ibrutinib treatment ultimately relapse on account of their tumors acquiring resistance to the drug.
By conducting a longitudinal study of mantle cell lymphomas with primary and acquired resistance to ibrutinib, researchers were able to identify a mutation in the target of ibrutinib, BTK, that they associate with resistance to the drug.
From there, researchers were able to develop rational drug combinations that could aid future patients with the same drug resistance.
In addition to mantle cell lymphoma, this study could also benefit treatment of other B cell lymphomas like CLL and certain non-Hodgkin lymphomas.
Genomic analyses provided explanations for these two types of drug resistance.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
- Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
- Cabozantinib Effective Regardless of PD-L1 Expression in RCC